{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:39:34Z","timestamp":1773866374077,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1136\/ijgc-00009577-200409000-00011","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T11:38:43Z","timestamp":1551872323000},"page":"804-814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients"],"prefix":"10.1016","volume":"14","author":[{"given":"S.","family":"Tangjitgamol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.T.","family":"See","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Manusirivithaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.F.","family":"Levenback","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0005","first-page":"5","article-title":"Cancer statistics 2003","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0010","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","article-title":"Moderate progress for ovarian cancer in the last 20 years: prolongation of survival but no improvement in the cure rate","volume":"38","author":"Engel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0015","first-page":"107","article-title":"Carcinoma of the ovary","volume":"6","author":"Heintz","year":"2001","journal-title":"J Epidemiol Biostat"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0025","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0030","series-title":"Proceedings of the Annual Meeting of the American Society of Clinical Oncology","first-page":"452","article-title":"Comparative study of disease process and survival in patients with recurrent serous low malignant potential tumor of ovary versus low grade serous carcinoma","author":"Shavartsman","year":"2003"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0035","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclopho-sphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/95.2.125","article-title":"International Collaborative Ovarian Neoplasm (ICON) collaborators. Inter-tio-1 Collaborative Ovarian Neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer","volume":"95","author":"Colombo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0050","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/cncr.2820710422","article-title":"Second-line chemotherapy for recurrent carcinoma of the ovary","volume":"71","author":"Thigpen","year":"1993","journal-title":"Cancer"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0055","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","article-title":"Developmental chemotherapy and management of recurrent ovarian cancer","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0060","first-page":"104","article-title":"Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum \u2013 a systematic review of the evidence from randomized trials","volume":"23","author":"Fung","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/gyno.1998.4997","article-title":"\u2018\u2018Recurrence within 6 months of platinumtherapy\u201d: An adequate definition of \u2018\u2018platinum-refractory\u201d ovarian cancer?","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s004320050177","article-title":"Evidence that a \u2018\u2018treatment-free interval of less than 6 months\u201d does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma","volume":"124","author":"Markman","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/gyno.2000.5958","article-title":"Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy","volume":"79","author":"Zanotti","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0080","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2002.20.5.1232","article-title":"Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens","volume":"20","author":"Cantu","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0085","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0090","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"Piccart","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/gyno.1998.5237","article-title":"Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer","volume":"72","author":"Bolis","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ijgc-00009577-200303000-00007","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0105","first-page":"368a","article-title":"Docetaxel for patients with ovarian cancer refractory to paclitaxel an update","volume":"18","author":"Kavanagh","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0110","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0115","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0120","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0125","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum- and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0090-8258(02)00021-5","article-title":"Threeconsecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer","volume":"88","author":"Brown JV","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0145","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pretreated patients with advanced epithelial ovarian cancer","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0150","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (20 20 difluorodeoxycytidine) in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.1994.12.1.60","article-title":"Oral etoposide is active against platinum-resistant epithelial ovarian cancer","volume":"12","author":"Hoskins","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0165","first-page":"439","article-title":"Capecitabine in treatment of platinum-resistant recurrent ovarian cancer","volume":"22","author":"Boehmer","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0170","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0175","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.1996.14.9.2546","article-title":"Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease","volume":"14","author":"Bajetta","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0180","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/gyno.2001.6458","article-title":"Why study third-, fourth-, fifth-, ... line chemotherapy of ovarian cancer?","volume":"83","author":"Markman","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0185","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1200\/JCO.2001.19.5.1266","article-title":"Does palliative chemotherapy palliate?. Evaluation of expectations outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer","volume":"19","author":"Doyle","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/gyno.2002.6748","article-title":"Treatment pReferences in recurrent ovarian cancer","volume":"86","author":"Donovan","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0195","first-page":"373","article-title":"Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients","volume":"79","author":"Villa","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-00009577-200409000-00011_bib0200","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24199355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24199355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-00009577-200409000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:16:25Z","timestamp":1753233385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24199355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":40,"aliases":["10.1111\/j.1048-891x.2004.014512.x"],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S1048891X24199355"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200409000-00011","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200409000-00011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Blackwell Publishing Ltd","name":"copyright","label":"Copyright"}]}}